The Virginia General Assembly has passed legislation to stop insurers and their pharmacy benefit managers (PBMs) from discriminating against 340B grantee covered entities and their contract pharmacies. Hospitals would be excluded from protection.
Virginia health centers say Gov. Glenn Youngkin
…
HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
Ryan White Clinics for 340B Access (RWC-340B) said
…
Medicare likely would pay 340B hospitals 106% of the average sales price (ASP) for Aduhelm—Biogen’s high-cost biologic drug for early-stage Alzheimer’s disease—for the first two or three years it is on the market, not the ASP minus 22.5% 340B hospital
…
The U.S. Centers for Medicare & Medicaid Services (CMS) asked a federal district judge in Sacramento last week to dismiss California health centers’ claims for relief over CMS’s approval of the state’s transfer of Medicaid managed care drug benefits to
…
Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. It is the 15th manufacturer to place restrictions on its 340B contract pharmacy program.
The policy, which applies to hospital
…
A federal district judge on Friday entered his final orders and judgement in AstraZeneca’s 340B contract pharmacy lawsuit, clearing the way for the government to file its anticipated appeal.
Judge Leonard Stark of the District of Delaware closed the first
…
President Biden is scheduled this afternoon to sign a $1.5 trillion federal appropriations bill with language to help some hospitals forced out of the 340B program during the COVID-19 pandemic.
The bill also gives the U.S. Health Resources and Services
…
Contract pharmacy growth patterns differ between 340B hospital and non-hospital entities, suggesting they may use 340B differently and should be subject to different 340B rules, new research in the American Journal of Managed Care concludes.
The authors, who previously have
…
Janssen Pharmaceuticals is giving 340B entities refunds for overcharges on 14 NDCs during the third and fourth quarters of 2019, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
“The revisions were due to
…
The U.S. Senate last night passed a $1.5 trillion federal appropriations bill with language to help some hospitals forced out of the 340B program during the COVID-19 pandemic.
The House passed the bill Wednesday night. President Biden is expected
…
×
*Sign up for news summaries and alerts from 340B Report